Breaking News

Tweet TWEET

Gen9 Receives $21 Million Strategic Investment From Agilent Technologies

  Gen9 Receives $21 Million Strategic Investment From Agilent Technologies

   Agilent’s Equity Stake Will Accelerate Growth and Innovation at Company
                  Pioneering Next-Generation Gene Synthesis

Business Wire

CAMBRIDGE, Mass. & SANTA CLARA, Calif. -- April 24, 2013

Gen9, Inc., a pioneer in the development of scalable technologies for
synthesizing genes, and Agilent Technologies (NYSE: A) today announced the
closing of a $21 million strategic investment from Agilent in Gen9. Gen9 will
use these funds to further invest in product development and to expand the
commercial infrastructure for its synthetic biology business. As part of this
investment, Agilent has secured an equity stake in the company and will join
its board of directors.

Gen9 is a privately held company with a portfolio of next-generation gene
synthesis technologies that enable the high-throughput, automated production
of DNA constructs at lower cost and higher accuracy than previous methods.
Together, these technologies form the foundation of the Gen9 BioFab^®
platform, which has the capacity to synthesize tens of thousands of gene
fragments in just a few square feet of laboratory space.

As part of this relationship, Gen9 will incorporate Agilent’s Oligonucleotide
Library Synthesis (OLS) technology into its manufacturing process to allow for
the large-scale creation of pathway constructs and DNA libraries. Agilent’s
OLS technology is the industry-leading platform for generating high-accuracy
oligos. Today, Gen9 is manufacturing and shipping double-stranded GeneBits™
DNA constructs, or gene fragments from 500 to 1,024 base pairs long.

“Gen9 was founded to significantly increase the world's capacity to
cost-effectively generate high-quality DNA content for use in transforming
industries ranging from chemical and enzyme production to agriculture,
biofuels, pharmaceuticals, and even data storage,” said Kevin Munnelly,
president and CEO of Gen9, Inc. “Agilent’s investment is a powerful validation
of our proprietary BioFab platform and we look forward to working closely with
them to further innovate around our manufacturing capabilities and build Gen9
into the leading high-throughput supplier to the synthetic biology
marketplace.”

“Synthetic DNA constructs have the potential to form the foundation of the
next revolution in industrial manufacturing, through biologically constructed
machines that can produce materials of high value and complexity. This
revolution will only be possible through the ability to routinely synthesize
and assemble high-quality, error-free DNA at much greater sequence lengths
than are currently available,” added Neil Cook, vice president and director,
Agilent Laboratories. “We believe that Gen9 has the correct strategy,
technology, team, and IP portfolio to complement Agilent’s innovations in
oligo library synthesis and, working together, we will help realize the
promise of synthetic biology.”

Agilent’s partnership with Gen9 complements the company’s existing investments
in synthetic biology, gene synthesis and assembly, including further
generations of its oligo synthesis technology. Agilent currently produces the
highest-quality long DNA compared to that of any commercially available
source. In addition, in 2011 Agilent launched a collaborative investment with
UC Berkeley’s Synthetic Biology Institute as its first Industry Member.
Agilent announced an earlier collaborative investment with Harvard
University’s Wyss Institute for Biologically Inspired Engineering in 2010.

Gen9 was founded in 2009 by Joseph Jacobson (Massachusetts Institute of
Technology), George Church (Harvard Medical School) and Drew Endy (Stanford
University). Additional Gen9 investors include Draper Fisher Jurvetson, The
Kraft Group, PBM Capital Group and a number of angel investors, including
Scott A. Schoen and Weili Dai.

For more information, please visit www.gen9bio.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company
and a technology leader in chemical analysis, life sciences, diagnostics,
electronics and communications. The company's 20,500 employees serve customers
in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal
2012. Information about Agilent is available at www.agilent.com.

About Gen9

Gen9 is building on advances in synthetic biology to power a scalable
fabrication capability that will significantly increase the world’s capacity
to produce DNA content. The privately held company’s next-generation gene
synthesis technology allows for the high-throughput, automated production of
DNA constructs at lower cost and higher accuracy than previous methods on the
market. Founded by world leaders in synthetic biology, Gen9 aims to ensure the
constructive application of synthetic biology in industries ranging from
enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is based
in Cambridge, Mass. and can be found online at www.Gen9Bio.com.

Gen9, GeneBits and BioFab are trademarks or registered trademarks of Gen9,
Inc. All other brands may be trademarks of their respective holders.

Contact:

For Gen9
Colin Sanford, 203-340-2441
colin@bioscribe.com
or
Agilent Technologies, Inc.
Eric Endicott, 408-553-2005
eric_endicott@agilent.com